Patricia Andrews Buys 35,400 Shares of Oncolytics Biotech (TSE:ONC) Stock

Oncolytics Biotech Inc. (TSE:ONC) Director Patricia Andrews acquired 35,400 shares of the business’s stock in a transaction on Thursday, February 12th. The shares were bought at an average price of C$1.18 per share, with a total value of C$41,772.00. Following the completion of the transaction, the director directly owned 78,128 shares of the company’s stock, valued at approximately C$92,191.04. The trade was a 82.85% increase in their ownership of the stock.

Oncolytics Biotech Stock Performance

Oncolytics Biotech Inc. has a 1 year low of C$0.44 and a 1 year high of C$2.08. The company has a market cap of C$1.50 billion, a P/E ratio of -40.27 and a beta of 0.80. The company has a current ratio of 2.99, a quick ratio of 8.86 and a debt-to-equity ratio of 11.75. The firm’s fifty day moving average is C$14.90 and its two-hundred day moving average is C$13.02.

Oncolytics Biotech (TSE:ONC) last announced its quarterly earnings results on Wednesday, November 12th. The company reported C($0.14) EPS for the quarter. Research analysts predict that Oncolytics Biotech Inc. will post -0.41 EPS for the current fiscal year.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.